EGFR and adenocarcinoma: More interestingly, we found that in the subgroup of patients with adenocarcinoma and EGFR mutation, the ones with methylated SFRP5 had a significantly shorter PFS (2.0 months), as compared to the ones with unmethylated SFRP5 (9.0 months) (P = 0.013, Logrank Test) (Figure 2D).